Transplantation in AML CR1.

摘要

In this issue of Blood, Gupta and colleagues report promising results using allo-SCT for patients with unfavorable cytogenetics in AML in CR1. Their data show long-term outcomes for HLA well-matched URD are comparable with those from MSD transplantations. These findings suggest that the allo-SCT approach can be extended to all patients with an HLA-identical donor. The data encourage application of CBT or haploidentical transplantations to these high-risk patients because the outcome of these procedures is improving and expected to be better than chemotherapy alone.